Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer

Academic Article


  • Purpose: Glycoprotein NMB (gpNMB), a novel transmembrane protein overexpressed in 40% to 60% of breast cancers, promotes metastases in animal models and is a prognostic marker of a poor outcome in patients. The antibody-drug conjugate glembatumumab vedotin consists of a fully human anti-gpNMB monoclonal antibody, conjugated via a cleavable linker to monomethyl auristatin E. Glembatumumab vedotin is generally well tolerated, with observed objective responses in advanced melanoma. This is, to our knowledge, the first study of glembatumumab vedotin in breast cancer.
  • Published In

    Digital Object Identifier (doi)

    Author List

  • Bendell J; Saleh M; Rose AAN; Siegel PM; Hart L; Sirpal S; Jones S; Green J; Crowley E; Simantov R
  • Start Page

  • 3619
  • End Page

  • 3625
  • Volume

  • 32
  • Issue

  • 32